Medivir announces that Simeprevir (TMC435) data will be presented at the upcoming AASLD Meeting

Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today that four abstracts
related to simeprevir (TMC435), have been accepted for presentation at the 63nd
Annual Meeting of the American Association for the Study of Liver Diseases
(AASLD), taking place from November 9-13 in Boston, USA.

Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III
clinical development for the treatment of chronic hepatitis C jointly developed
by Medivir and Janssen Research & Development Ireland (Janssen).

AASLD PRESENTATIONS
Two of the abstracts will be presented as oral presentations and two as posters
at the Hynes Convention Center in Boston.

ORAL PRESENTATIONS
Parallel Session 12, HCV New Agents: Hard to Treat Patients, Hynes Ballroom B &
C, November 11, 16:45-18:15

  · Efficacy and tolerability of TMC435 150 mg once daily with peginterferon α
-2a and ribavirin for treatment of HCV genotype 1 infection in patients with
Metavir score F3 and F4 (PILLAR and ASPIRE trials)
Fred Poordad, Michael W. Fried, Stefan Zeuzem, Peter Ferenci, Oliver Lenz, Rekha
Sinha, Katleen Callewaert, Monika Peeters, Maria Beumont-Mauviel

  · No clinically significant interaction between the investigational HCV
protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus
Sivi Ouwerkerk-Mahadevan, Alexandru Simion, Steven Mortier, Monika Peeters,
Maria Beumont Mauviel

POSTER PRESENTATIONS
Clinical HCV 1, Poster Hall, November 11, 08:00-17:30

  · Safety and tolerability of TMC435 in combination with peginterferon α-2a and
ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and
-experienced patients (Phase IIb PILLAR and ASPIRE trials)
Michael W. Fried, Fred Poordad, Stefan Zeuzem, Peter Ferenci, Oliver Lenz, Sivi
Ouwerkerk-Mahadevan, Monika Peeters, Rekha Sinha, Maria Beumont-Mauviel

  · No pharmacokinetic interaction between the investigational HCV protease
inhibitor TMC435 and an oral contraceptive containing ethinylestradiol and
norethindrone
Sivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Kurt Spittaels, Alexandru
Simion, Monika Peeters

The abstracts have been published today and can be accessed on the AASLD
website: http://www.aasld.org.

For more information about Medivir, please contact:

Medivir                      Direct: +46 8 440 6550 or:
Rein Piir, EVP Corporate     Mobile: +46 708 537 292
Affairs & IR
M:Communications             medivir@mcomgroup.com
Europe: Mary-Jane Elliott,   +44(0)20 7920 2330
Amber Bielecka, Hollie Vile

About Simeprevir (TMC435)
Simeprevir is is a once daily potent HCV NS3/4A protease inhibitor jointly
developed by Medivir and Janssen Research & Development Ireland (Janssen) to
treat chronic hepatitis C virus infections.

Simeprevir is being developed both in combination with PegIFN/RBV and in
combination with other Direct-acting Antiviral (DAA) agents in an all oral
Interferon (IFN) free regimen, with or without Ribavirin (RBV).

Simeprevir is currently being evaluated in three global phase III studies, QUEST
-1 and QUEST-2 in treatment-naïve patients and PROMISE in patients who have
relapsed after prior PegIFN/RBV-treatment. In parallel to these trials, phase
III studies for simeprevir in Japan, in both treatment naive and treatment
experienced hepatitis C genotype-1 infected patients, are ongoing.

In parallel with the ongoing global phase III-studies, simeprevir is currently
in three phase II Interferon free trials with or without Ribavirin.

  · In the first trial simeprevir is evaluated in combination with GS7977
(Gilead) in null responder hepatitis C genotype-1 infected patients.
  · In the second trial simeprevir is evaluated in combination wtih daclatasvir
(BMS) in treatment-naïve or previous null responder hepatitis C genotype-1
infected patients.
  · In the third trial simeprevir is evaluated in combination with TMC647055
(Janssen R&D) and ritonavir in low doses in treatment-naïve, relapser or null
responder hepatitis C genotype-1 infected patients.

For additional information about simeprevir (TMC435) please see
www.clinicaltrials.gov

About Hepatitis C
Hepatitis C is a blood-borne infectious disease of the liver and is a leading
cause of chronic liver disease and liver transplants. The World Health
Organization estimates that nearly 170 million people worldwide, or
approximately 3% of the world's population, are infected with hepatitis C virus
(HCV). The CDC (Centers for Disease Control and Prevention) has reported that
more than three million people in the United States are chronically infected
with HCV.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir
(TMC435), a novel protease inhibitor in phase III clinical development for
hepatitis C that is being developed in collaboration with Janssen Research &
Development Ireland.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia
and today Medivir has a broad product portfolio with prescription
pharmaceuticals in the Nordics.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, is
launched in collaboration with GlaxoSmithKline to be sold OTC under the brand
name ZoviDuo in Europe, Japan and Russia.

Medivir’s IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company’s website:
www.medivir.com

Medivir is a collaborative and agile pharmaceutical company with an R&D focus on
infectious diseases and a leading position in hepatitis C. We are passionate and
uncompromising in our mission to develop and commercialize innovative
pharmaceuticals that improve people’s lives.